Notes. It's never easy to shepherd a penny stock into dollar land. The psychological barrier from 99c to $1.00 is daunting compared to the hurdle from $1.99 to $2.00. Since Jan 2003, CTUM has breached the one-dollar wall only once (mid-2004--long before most, if not all of us purchased shares).
CTUM, with present market cap of $28.5 million ($.85/sh) and zero earnings, is obviously betting on forward revenues and profits, based on its globally patented technologies and other interests. Many of us here agree this is a pretty good gamble, as gambles go.
CTUM tells us FDA filing [presumed 510(k)] will occur before April 1st dawns. This means the first FDA filing for application of revolutionary Live Tissue Connect (LTC) could occur at any instant during March. There is little doubt such an event will create quite a stir not only among investors and financial houses, but also throughout the medical arts community. After all, how often is the book on medical surgical practice completely rewritten?
Lest we forget, LTC replaces sutures, clamps, sealants and glues. (Some of these modalities have histories dating back thousands of years. Sutures, e.g., hearken back to ancient Egypt.) LTC produces healing with little or no scarring and necrosis (death of living tissue). Surgery and post-operative recovery time are both halved.
After LTC takes its rightful place as mainstream surgical practice, there will be those who will wonder, in stunned amazement, how CTUM could ever have traded under a dollar.
These are my opinions and sentiments only. Take them for what they're worth. Do your DD. Buying stocks is risky!
"If we could sell our experiences for what they cost us, we'd all be millionaires." -Abigail van Buren (a/k/a Dear Abby)
